Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multi-center study of ixazomib, pomalidomide, and dexamethasone for relapsed or refractory multiple myeloma
KCT0010931Phase 2Not yet recruiting
- Sponsor
- Takeda
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ixazomib, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Takeda. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ixazomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0010931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010931.